comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-30 01:13:59 - browse：3865

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Cognito secures funding to test medical device for Alzheimer's

Wikipedia

WSS

Commercial surrogacy can be ethical, despite pope’s claims

Biden administration opens offers in Medicare drug price negotiations

Apple Vision Pro: A first look at health apps on the new VR headset

Is there really a nursing shortage in the U.S.?

Woodcock on FDA’s accelerated approval and her next chapter

ADCs take center stage as promising cancer treatments

hotspot

comprehensive

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Activists slam private health insurers over coverage restrictions

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

DIEP, the 'gold standard' of breast reconstruction, is under threat

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Some dementia cases could be undiagnosed liver disease

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Study on Amgen’s bispecific immunotherapy produces positive data

Wikipedia

Some dementia cases could be undiagnosed liver disease

Vertex non

SAMSHA loosens regulations on methadone treatment centers

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

How AI can help patients find reliable information about doctors

ADCs take center stage as promising cancer treatments

Wikipedia

knowledge

Wikipedia

focus